Adverum Biotechnologies, Inc. is a biotechnology company focusing on developing gene therapies for serious ocular and rare diseases. The company's primary mission is to deliver durable, single-administration treatments that address unmet medical needs by utilizing its innovative vector platform tailored for therapeutic gene delivery. Adverum's lead product candidate tackles retinal diseases including wet age-related macular degeneration and diabetic macular edema, conditions known for causing significant vision loss. By concentrating on these severe ocular disorders, Adverum plays a significant role in transforming the landscape of ophthalmic care. It collaborates with various research institutions and industry experts to advance its gene therapy approach. Headquartered in Redwood City, California, Adverum leverages cutting-edge science and a commitment to patient care to make a meaningful impact in the biotechnology and healthcare sectors. Its work reflects the potential of gene therapy solutions to provide long-lasting treatments, thereby influencing the future direction of regenerative medicine and patient care in specialized medical fields.